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Proton MR spectroscopy of the brain at 3 T:
an update
Abstract Proton magnetic resonance
spectroscopy (1H-MRS) provides
specific metabolic information not
otherwise observable by any other
imaging method. 1H-MRS of the brain
at 3 T is a new tool in the modern
neuroradiological armamentarium
whose main advantages, with respect
to the well-established and technolog-
ically advanced 1.5-T 1H-MRS, in-
clude a higher signal-to-noise ratio,
with a consequent increase in spatial
and temporal resolutions, and better
spectral resolution. These advantages
allow the acquisition of higher quality
and more easily quantifiable spectra
in smaller voxels and/or in shorter
times, and increase the sensitivity in
metabolite detection. However, these
advantages may be hampered by
intrinsic field-dependent technical
issues, such as decreased T2 signal,
chemical shift dispersion errors,
J-modulation anomalies, increased
magnetic susceptibility, eddy current
artifacts, challenges in designing and
obtaining appropriate radiofrequency
coils, magnetic field instability and
safety hazards. All these limitations
have been tackled by manufacturers
and researchers and have received
one or more solutions. Furthermore,
advanced 1H-MRS techniques,
such as specific spectral editing,
fast 1H-MRS imaging and diffusion
tensor 1H-MRS imaging, have been
successfully implemented at 3 T.
However, easier and more robust
implementations of these techniques
are still needed before they can
become more widely used and
undertake most of the clinical and
research 1H-MRS applications.
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Introduction
Proton magnetic resonance spectroscopy (1H-MRS) of the
brain is a non-invasive technique that supplies information
about the presence and levels of different low-molecular
weight chemicals. The metabolites detectable with 1H-MRS
include the prominent resonances of N-acetylaspartate
(NAA), choline (Cho) and creatine (Cr), and a variety of
other resonances that might or might not be evident
depending on the type and quality of spectra as well as on
the pathological condition [1–3]. Several metabolites, such as
lactate in epilepsy or mitochondrial disorders [3], phenyl-
alanine in phenylketonuria [4], guanidinoacetate in guani-
dinoacetate methyltransferase deficiency [5] and glycine in
nonketotic hyperglycinemia [6], can be observed only when
their concentrations are several times higher than normal.
1H-MRS has been utilized to identify and characterize
the metabolic changes associated with many neurological
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disorders. The list is very long and includes brain tumors,
degenerative diseases such as Alzheimer’s, Huntington’s
and Parkinson’s diseases, cerebrovascular diseases, meta-
bolic disorders such as adrenoleukodystrophy and Cana-
van’s disease, epilepsy, multiple sclerosis and systemic
diseases such as hepatic and renal failure [1–3]. Rare
diseases also studied include creatine deficiency syndrome
[7], variant Creutzfeldt-Jakob Disease [8], pantothenate
kinase-associated neurodegeneration [9] and Rasmussen’s
encephalitis [10]. Most of these studies have been
performed using devices operating at 1.5 T, which has
been considered the standard field for years.
In the last decade, with the approval of the US Food and
Drug Administration for clinical use, MR systems at 3 Tare
proliferating, particularly at research centers [11]. With
respect to the well-established MR technique at 1.5 T,
switching to a higher field brings several advantages, such
as an increased signal-to-noise ratio, with consequent
enhanced spatial and temporal resolutions, and better
spectral resolution, but also many limitations, such as
installation issues, higher acoustic noise, device compat-
ibility, system inhomogeneity, eddy current artifacts,
misregistration errors, J-modulation anomalies, magnetic
field instability and safety restrictions. Some technical
characteristics, such as changes in relaxation times,
chemical shift and susceptibility, can have both benefits
and disadvantages [11–15]. These limitations necessitating
changes in technical devices and acquisition strategies have
led to a debate about the usefulness of higher field strength
in clinical settings [14–20]. However, the new generation
of 3-T systems presents a number of fundamental technical
differences with respect to the first generation, which have
reduced the concerns about the limitations as well as the
benefits of 3-T over 1.5-T systems and increased the
penetration of 3-T scanners into the clinical setting [18–
20]. Furthermore, adapting the imaging procedures to
changes produced by the higher field allows obtaining
images with quality and/or acquisition speed superior to
1.5 T [21, 22]. A number of recent studies have evidenced
the advantages of 3 Tover 1.5 T for both conventional MRI
and MR applications limited by insufficient sensitivity,
such as MR angiography, functional MRI and 1H-MRS
[19, 20, 23, 24]. This review focuses on brain 1H-MRS at
3 T, illustrating the advantages, the strategies to overcome
the limitations and the advanced techniques.
Advantages and disadvantages of 1H-MRS at 3 T
Signal-to-noise ratio
The intensity of the MR signal is correlated linearly with
the strength of the static magnetic field. Thus, in theory, the
signal-to-noise ratio (SNR) would double when moving
from 1.5 T to 3 T, but in practice the improvement ranges
only from 20% to 50% [25–28]. In effect, the SNR depends
on several other variables, such as T1 and T2 relaxation
times, type of sequence, number of signal averages, size of
sample volume, radiofrequency (RF) effects and shimming
efficacy. T1 relaxation times increase at 3 T, leading to
increased signal saturation for a given repetition time,
while T2 relaxation times decrease. Therefore, the
theoretical doubling of SNR cannot be achieved, owing
to the use of repetition times (TR) in the order of the T1
decay times (and not infinitely long) and echo times (TE) in
the order of the metabolite T2 decay times (and not close to
0) [25]. Furthermore, SNR declines progressively with the
increase of TE, passing from values ∼35% better than 1.5 T
at TE 30 ms, to values less than 25% at TE 144 ms, and to
equity at TE 288 ms [28].
One of the possible approaches to increase the SNR is
the use of multiple receiver coils. Awell-designed phased-
array (PA) head coil, in fact, has sensitivity significantly
superior to that of the birdcage-type volume coil, which is
more widely used. The SNR increases with the number of
coil elements, mainly for the regions next to the coil array
and to a lesser extent for those towards the center of the
imaged object [29]. The signals obtained from the different
coil elements can be combined by several processing tools,
including nonparametric, semiparametric and parametric
ones, selected on the basis of available prior knowledge
about the data [30]. A surface PA coil can provide
approximately a ten-fold increase in SNR at the brain
cortex as compared to a standard head coil [31].
Spatial and temporal resolution
The increased SNR associated with higher magnetic fields
permits shorter imaging times for a given spatial resolution,
higher resolution for a given imaging time or the
combination of both. The advantages of shorter examina-
tion times for patients, radiologists, technicians and
hospital administrators are obvious. Higher spatial resolu-
tion improves the matching of metabolic and anatomical
information, enhancing the clinical value of 1H-MRS [11].
Spectra can be acquired from single-voxel, or from two-
dimensional (2D) or three-dimensional (3D) multivoxels
that are generally referred to as chemical shift imaging
(CSI), spectroscopic imaging (SI) or MRS imaging (MRSI)
(Fig. 1). At 1.5 T, most 1H-MRS studies have been
performed with a spatial resolution of 1 cm3 or more, while
the resolution of routine MRI is about 1 mm3 [32]. At 3 T,
voxels well below 1 cm3 can be obtained with good SNR
and acceptable acquisition times (Fig. 1) [25, 31, 32].
Using a birdcage head coil, 3D MRSI with 0.75 cm3
resolution can be obtained in 27 min [25, 32], and to retain
the lowest SNR of 1.5 T at 3 T, the acquisition time can be
shortened 26%, from 27 min to 17 min [25]. Using a high-
sensitivity PA head coil, 3D MRSI with a voxel size of
0.34 cm3 can be acquired in 9.5 min [31]. Considering that
gray matter is typically about 5 mm thick, a spatial
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Fig. 1 Example of 2D-multivoxel proton spectroscopic imaging
(1H-MRSI) performed using a 3.0-T MR scanner (Signa Horizon
LX) with a standard head coil, and the protocol (PROBE/SI) and the
software (Functool Performance) provided by the manufacturer
(General Electric Medical Systems, Milwaukee, WI). In brief, a
point-resolved spectroscopy (PRESS) pulse sequence, with repeti-
tion time (TR) 1,500 ms, echo time (TE) 144 ms, field of view
(FOV) 24 cm, phase 16, section thickness 10 mm and acquisition
time 6 min 53 s, provided a spectroscopic data set, which was
spatially zerofilled to 32×32 images with a final voxel resolution of
7.5×7.5×10 mm (0.56 cm3). Fluid-attenuated inversion recovery
(FLAIR) (a) and contrast-enhanced T1-weighted (b) images from a
45-year-old man with a left fronto-temporo-parietal glioblastoma.
Choline (Cho) (c), N-acetylaspartate (NAA) (d), creatine (Cr) (e)
and lactate/lipids (LL) (f) maps. Localizing FLAIR image (g) and
spectra (1–6) from the corresponding boxes in g. Color scale: red
strongest signal intensity; blue weakest signal intensity. Higher
spatial resolution improves the ability to recognize the spatial
heterogeneity of high-grade gliomas. The spectrum 1, showing a
low level of Cho, undetectability of Cr and NAA, and high LL peak,
suggests the presence of necrosis. The spectrum 2, in the margins of
glioma, presents the typical tumor pattern, characterized by an
abnormal Cho/NAA ratio (<1). The spectra 3 and 4, in an apparently
edematous region surrounding the enhanced margins of glioma,
show low metabolite levels, as compared to the normal spectra 5 and
6, but different pattern: the spectrum 3 has a tumor pattern and
suggests the presence of infiltrating tumor cells; the spectrum 4 has a
normal Cho/NAA ratio and suggests noninfiltrated vasogenic edema
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resolution of 0.34 cm3 can allow the detection of differ-
ences between gray and white matter metabolite levels,
avoiding partial volume effects. With a surface PA coil, 3D
MRSI data with a spatial resolution as fine as 0.09 cm3 can
be acquired in 17 min [31].
Spectral resolution and metabolite quantification
Spectral resolution, i.e., the ability to distinguish adjacent
peaks in a spectrum, mainly depends on spectral distance,
i.e., the difference in resonance frequency between two
metabolites, and on attainable linewidth, i.e., the width at
half-height of the metabolite resonance in Hz. The spectral
distance (in Hz) is linearly correlated with the field
strength and is about twice at 3 T as compared to 1.5 T
(Fig. 2). The attainable linewidths are an inverse function
of field-dependent T2 relaxation times and magnetic field
homogeneity. Despite shorter T2 times and higher field
inhomogeneity producing linewidths larger than at 1.5 T,
the doubling of spectral distance at 3 T yields a better
spectral resolution [25, 26]. This is reflected by improved
baseline separation of Cho and Cr, which are only 0.2 parts
per million (ppm) apart [25], and by better resolution of the
glutamate/glutamine region, between 2.05 and 2.5 ppm, at
shorter TE (Fig. 3) [26]. Nevertheless, despite the better
spectral resolution and higher SNR, the reproducibility of
metabolite measurements at 3 T is similar to [28, 33] or
even worse than [27] that at 1.5 T. This shortfall can be
explained by the larger linewidths at 3 T, decreasing both
the SNR and the precision of quantitative analysis [27].
High spatial resolution at 3 T, however, reduces the
magnetic field inhomogeneity and hampers the contraction
of T2, decreasing the linewidths, especially for voxels
below 0.75 cm3. This produces standard errors of the mean
comparable in different measurements, suggesting the
possibility of achieving high-precision quantification at
those resolutions [32]. Unfortunately, studies focusing on
the accuracy and precision of metabolite measurements at
3 T in high-resolution voxels are lacking.
The measurement of metabolite relaxation times is
crucial for a reliable and reproducible determination of
absolute metabolite concentration. While the T1 relaxation
time of water protons is significantly longer at 3 T as
compared to 1.5 T, metabolite T1 measurements can be
either longer [34] or almost unchanged [35, 36]. The
discrepancies can be explained by the large interindividual
variability at 1.5 T and the possible differences in scanner
performance, sequence design and strategies for acquiring
and evaluating spectra. Another factor that can contribute
Fig. 2 Comparison of single-
voxel spectra obtained with (c) a
1.5-T MR scanner (Signa Echo
Speed) and (d) a 3-T scanner
(Signa Horizon LX), using the
protocol (PROBE-P) and the
software provided by the man-
ufacturer (General Electric
Medical Systems, Milwaukee,
WI). a Localizing T2-weighted
image showing a low-grade
glioma in the left temporal lobe
of a 43-year-old woman. b
Spectra recorded at 1.5 T (red)
and 3 T (black), using PRESS
sequence with TR 2,000 ms, TE
144 ms, 128 averages, voxel
size 2.0×2.0×2.0 cm and
acquisition time 4 min 56 s, and
overlapped for emphasizing
the differences. At 3 T, the
signal-to-noise ratio (SNR) is
about 25% higher and the
spectral distance between the
metabolites (in hertz) is doubled
1654
to the variability is the T1 regional differences reported
both at 3 T and 1.5 T [34, 36]. Ethofer et al. [34], for
example, reported metabolite T1 values only slightly longer
at 3 T vs. 1.5 T in the occipital lobes and cerebellum, and
significantly increased at 3 T in the motor cortex,
frontoparietal WM and thalamus (Table 1). Contrarily,
metabolite T2 relaxation times at 3 T are markedly reduced
as compared to 1.5 T (Table 1) and show distinct regional
variations, especially for NAA. These region-specific
variations and the different T2 effect on NAA, Cho and
Cr have to be taken into account when using T2 values for
absolute quantification. Furthermore, due to the decreased
T2, MRS protocols with shorter TE values are preferable at
3 T, while TR adjustments appear of minor importance
because of controversial T1 relaxation changes [36].
Static (B0) and radiofrequency (B1) magnetic field
inhomogeneity
Awide variety of factors can alter the homogeneity of static
(B0) and radiofrequency (B1) magnetic fields, affecting the
quantitative and qualitative analyses of spectra. B0
inhomogeneities depend mainly on the effects linked to
magnetic susceptibility, i.e., the ability of a substance to
become magnetized. All paramagnetic and diamagnetic
tissue compartments as well as implanted metallic
structures affect B0 in different ways, inducing magnetic
field distortions directly correlated to the applied magnetic
field. Examples of susceptibility artifacts are those
occurring near the air-filled sinuses, the skull base and
the calvaria, provoked by susceptibility differences at
tissue interfaces. A variety of susceptibility artifact correc-
tion methods have been proposed, including gradient
compensation or z-shim techniques, tailored RF pulses,
active and passive shimming and post-processing [42].
B1 inhomogeneities derive from several factors, includ-
ing: imperfections in the RF pulse profile, an inhomoge-
neous transmit field, nonuniform reception sensitivity, RF
penetration effects and eddy currents. These problems
become more pronounced at high magnetic fields where
RF wavelengths in tissue become shorter. Methods to
reduce the effects of B1 inhomogeneity include: postpro-
cessing with or without prior knowledge of the B1 field
distribution; the use of tailored, adiabatic and composite
RF pulses; special coil designs; the use of dielectric
padding; optimizing current magnitudes and phases (RF
shimming). These methods have both advantages and
disadvantages [43, 44].
Eddy currents are small electric currents that are more
prominent at high field strengths because of the increased
speed and power of gradient coils. They can create an
additional magnetic field and therefore cause spectral
distortion and loss in SNR [45]. Furthermore, they can
induce considerable torque on metallic instruments and
implants, which can exceed the current limits of MR safety
[46]. Besides dedicated hardware designs including mag-
netic field gradient and shim pulse-shaping networks [47],
the effects of eddy currents can be minimized by correcting
algorithms using the water signal as a reference [45].
Schulte et al. [48] have proposed an efficient 2D eddy
current correction procedure, based on a 1D phase
deconvolution method.
Fig. 3 Spectral resolution of the
glutamate/glutamine (Glx) region
with different proton spectro-
scopic approaches. a,b Localized
spectra recorded in in vivo
at 1.5 T and 3 T (scanners as in
Fig. 2), using PRESS with TR
2,000 ms, TE 35 ms and 128
averages. The spectrum at 3 T
shows higher SNR and better
resolution of Glx region, between
2.1 and 2.5 parts per million
(ppm). c,d,e TE-averaged
PRESS: spectra form a phantom
acquired by JPRESS with 16
different TE ranging from 35 to
195 ms (c), spreading the signal
information into two spectral
dimensions, and resulting spec-
trum (d); spectrum obtained in
vivo from a healthy subject (e).
TE-averaged PRESS fully
resolves the glutamate (Glu) at
2.38 ppm from glutamine
overlap, resulting in its
unobstructed detection
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Chemical shift misregistration and J-modulation
artifacts
Localization techniques, such as point-resolved spectros-
copy (PRESS) or, to a lesser extent, stimulated-echo
acquisition mode (STEAM), cause chemical shift displace-
ment artifacts, which can give rise to signal misregistration
for almost all metabolites. Only the signal from one
specific frequency, usually NAA, originates from the
selected VOI, while signals from molecules with different
chemical shifts stem from spatially shifted volumes.
Chemical shift displacement approximately scales with
the square of the magnetic field strength, and this is partly
due to reduced RF pulse bandwidths as well as increased
chemical shift frequency separation [49]. There are several
ways to minimize these artifacts, including the choice of
Table 1 Published T1 and T2 relaxation times of NAA, Cho and Cr at 1.5 T and 3 T in different brain regions
Region/field strength [Ref.] T1 of NAA
a (s) T1 of Cho
a (s) T1 of Cr
a (s)
Occipital GM, 1.5 T [34] 1.27±0.05 1.15±0.12 1.24±0.06
Occipital GM, 1.5 T [37] 1.29±0.25 1.39±0.38 1.29±0.19
Occipital GM, 1.5 T [38] 1.27±0.22 1.01±0.16 1.39±0.16
Occipital GM, 3 T [34] 1.47±0.08 1.25±0.22 1.33±0.13
Occipital GM, 3 T [35] 1.47±0.13 1.30±0.13 1.46±0.16
Motor cortex, 1.5 T [39] 1.46 1.44 1.25
Motor cortex, 1.5 T [34] 1.17±0.07 1.08±0.16 1.16±0.10
Motor cortex, 3 T [34] 1.46±0.22 1.47±0.20 1.38±0.16
Thalamus, 1.5 T [40] 1.40b 1.20b 1.75b
Thalamus, 1.5 T [34] 1.41±0.09 1.10±0.17 1.27±0.11
Thalamus, 3 T [34] 1.57±0.08 1.38±0.22 1.45±0.16
Cerebellum, 1.5 T [40] 1.70b 1.50b 1.50b
Cerebellum, 1.5 T [34] 1.42±0.15 1.22±0.16 1.33±0.18
Cerebellum, 3 T [34] 1.43±0.19 1.26±0.11 1.38±0.09
Occipital WM, 1.5 T [40] 1.45b 1.15b 1.35b
Occipital WM, 1.5 T [41] 1.63 1.56 1.67
Occipital WM, 1.5 T [34] 1.36±0.06 1.03±0.15 1.24±0.10
Occipital WM, 3 T [35] 1.35±0.27 1.08±0.13 1.24±0.16
Occipital WM, 3 T [34] 1.40±0.15 1.17±0.15 1.31±0.13
Fronto-parietal WM, 1.5 T [34] 1.19±0.09 1.04±0.12 1.15±0.08
Fronto-parietal WM, 3 T [34] 1.56±0.06 1.21±0.13 1.40±0.06
Region/field strength [Ref.] T2 of NAA
c (ms) T2 of Cho
c (ms) T2 of Cr
c (ms)
Occipital GM, 1.5 T [37] 388±11 395±55 207±4
Occipital GM, 3 T [35] 247±19 207±16 152±7
Motor cortex, 1.5 T [36] 317±25 300±33 208±14
Motor cortex, 3 T [36] 247±13 222±15 162±16
Occipital WM, 1.5 T [41] 369±124 309±84 195±41
Occipital WM, 1.5 T [40] 450b 330b 240b
Occipital WM, 1.5 T [36] 361±39 330±44 215±15
Occipital WM, 3 T [35] 295±29 187±20 156±20
Occipital WM, 3 T [36] 301±18 222±17 178±9
Centrum semiovale, 1.5 T [26] 480±35 400±35 270±22
Centrum semiovale, 3 T [26] 210±9 180±18 150±18
GM gray matter; WM white matter
a Values are mean ± SD
b Median
c Values are mean ± SE
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frequency-encoding direction, field of view and receiver
bandwith, and the use of fat-suppression techniques, such
as inversion recovery sequences, very selective suppres-
sion (VSS) pulses, echo-planar spectroscopic imaging
(EPSI), spectral spatial pulses and postprocessing ap-
proaches [49, 50]. Ozturk-Isik et al. [50] have recently
proposed a postprocessing method, using a sensitivity-
encoding (SENSE) algorithm, to reduce contamination
from aliasing lipid resonances in 3D MRSI. This method is
effective for data acquired at 3 T using a multichannel RF
coil and high bandwidth, very selective saturation (VSS)
pulses.
J-modulation anomalies refer to signal loss or cancella-
tion of homonuclear-coupled resonances, arising from their
chemical shift separation. The extent of the signal loss can
vary considerably depending on the field strength, the used
coil and the sequence parameters. One example is the
doublet at 1.33 ppm of lactate, which can completely
disappear at 3 T for TE 144 ms. Strategies to prevent or
alleviate the signal loss due to anomalous J-modulation
present both advantages and disadvantages [12, 49, 51].
Magnetic field stability
Magnetic field instability is another factor that can affect
the quality of acquired spectra. In fact, even small drift of
B0 can result in measurable resonance frequency shift
during the 1H-MRS acquisition, causing suboptimal water
suppression, broadening of spectral lines and loss of phase
coherence. Spectral distortion due to field instabilities,
particularly concerning the high-field systems, can be
compensated for by dedicated correction algorithms [52].
An additional source of instability at higher fields is the
resonance frequency drifts induced by gradient heating.
These drifts can be corrected by the method recently
proposed by Ebel and Maudsley [53], which allows for
obtaining both a nonlocalized B0 measurement and a fully
phase-encoded water reference signal, and then for
correcting the frequency drift during postprocessing using
the measured values. The correction largely improves
spectral quality, removing lineshape distortions and
recovering metabolite signal loss.
Physiological motion, such as breathing and cardiac/
arterial pulsation, is another source of SNR loss and
adverse consequences on 1H-MRS acquisition. However,
its effects on brain PRESS at 3 T are negligible, implying
that cardiac gating and breath pacing/gating are not
routinely required for such an approach [54].
Safety issues
As B0 increases, the amount of RF power required by pulse
sequences also increases and can entail several biological
hazards. The specific absorption rate (SAR), namely the
measure of energy absorbed from the effects of RF pulses,
is four times higher at 3 T vs. 1.5 T and places some limits
on the clinical setting. These can manifest as a reduction in
slice number per TR period, longer scanner time and
“patient cooling” delays between sequences. However,
later-generation 3-T devices, which have new, more SAR-
efficient system designs, innovative pulse sequence
manipulations, parallel imaging and more appropriate
imaging protocols, have limited the rate of RF energy
deposition and should shortly lead to RF limitation and
section acquisition equal to or slightly greater than those
currently in place at 1.5 T [20]. A number of implants and
devices (clips, stents, prostheses, etc.) have been assessed
for magnetic field interactions at 3 T, and of these only 4%
have been potentially unsafe [55].
Advanced 1H-MRS techniques at 3 T
Spectral editing
Any technique that simplifies the appearance of a spectrum
for better observation and quantification of one or more
metabolites of interest can be considered a spectral editing
technique. Most of these techniques rely on the phenom-
enon of homonuclear or heteronuclear spin coupling, also
known as J-coupling, which is responsible for several
spectral patterns such as the doublet of lactate or the
multiplet of γ-aminobutyric acid (GABA). Several editing
sequences cannot be applied with 1.5-T scanners since they
need higher SNR and sufficient spectral resolution.
Examples of unresolved metabolites due to the J-coupling
phenomenon are the Glx-components glutamate, glutamine
and GABA, which cannot be easily differentiated from
each other at 1.5 T and therefore have been frequently
treated as a metabolite group [49, 51, 56–58].
Glutamate (Glu), the major excitatory neurotransmitter
of the central nervous system, has neurotoxic properties,
which have been associated with several neurodegenera-
tive diseases. Glu gives rise to a complex spectrum
characterized by the coupled spins of the C2–C4 hydrogen
nuclei and the overlaps with other resonances, especially
glutamine (Gln), glutathione and NAA. Glu and Gln, in
particular, have a very similar chemical structure and
overlap in their multiplet resonance groups. The editing
approaches implemented at 3 T to resolve Glu include the
multiple-quantum filter (MDF) procedure [56], more
recently modified by Schubert et al. [57], and 2D J-
resolved spectroscopy, dubbed JPRESS since it employs
PRESS for volume localization [48]. The MQF method
utilizes coherence transfer between different spin quantum
states as well as gradient filtering to select the signal of one
metabolite specifically and to suppress interfering signals.
However, it has the disadvantage of simultaneously
suppressing signals from Gln, NAA and myo-inositol,
which are of diagnostic value [59]. JPRESS consists of a
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series of spin-echo experiments with different echo times
spreading the signal information into two spectral dimen-
sions [48]. Interesting variants of JPRESS implemented at
3 T include: chemical shift-selective filter (CSSF) [58], TE-
averaged PRESS (Fig. 3) [59], constant time (CT) PRESS
[60] and maximum-echo sampling [48]. All these proce-
dures have been applied to a single voxel with a size ranging
from 8 cm3 to 15.6 cm3. Srinivasan et al. [61] have recently
proposed a TE-averaged PRESS technique for 2D 1H-MRSI
(TE-averaged MRSI) to generate glu maps with a spatial
resolution of 1.8 cm3 and a scan time of about 21 min.
Prior-knowledge fitting (ProFit) of J-resolved spectra is
a novel method that utilizes a 2D fitting procedure, namely
LCModel (linear combination of model spectra) in the
frequency domain and VARPRO (variable projection) in
the time domain, applied to JPRESS. Beside glutamate, it
shows the detectability of a wide range of metabolites,
including myo-inositol, glutathione, scyllo-inositol,
GABA, alanine and ascorbic ac [62].
For selectively measuring both Glu and Gln, Choi et al.
[63] have recently proposed a single-voxel, spectrally-
selective refocusing method, which allowed the measurement
Fig. 4 Demonstration of parallel acquisition technique using a
prototype 3D PRESS sequence with an array spatial sensitivity
encoding technique (ASSET). The experiments were performed on a
3.0-T MR scanner (GE EXCITE III HDTM 3 T) using an eight-
channel receive-only head coil. The sequence performance was
evaluated using a phantom containing water and lipid. The total
acquisition time of the fully sampled data was 8 min 32 s (3D
PRESS, TR=1,000 ms, TE=35 ms, FOV=26 cm, 3D phase
encoding steps =8×8×8) and could be reduced to 1 min 4 s by
means of data undersampling with a reduction factor of two in all
three spatial dimensions. All data were reconstructed and visualized
using Matlab (The Mathworks, Version 7.1.0.124 SP 3). a Axial
view of the phantom with the selected volume of interest. b Spectra
from the selected region of interest. The dotted box shows the
corresponding folded region of interest. c Spectrum within the green
box showing original and undersampled data. Typically for the
folding effect is the resulting summation of metabolite intensities,
yielding higher peak amplitudes. d Reconstructed spectrum after 3D
MRSI sensitivity encoding, which is in good agreement to the
reference (fully sampled) spectrum
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of these metabolites with negligible contamination fromNAA
and glutathione.
GABA is the major inhibitor neurotransmitter in the
human brain and has been implicated in several neurolog-
ical and psychiatric disorders. Due to its low concentration,
intense overlapping signals and complex spin system,
GABA measurement is particularly challenging at field
strengths accessible to clinical studies. A number of
spectral editing techniques have been proposed in an
attempt to resolve GABA. The techniques successfully
implemented at 3 T include: single quantum difference
spectroscopy (SQDS) [64], STEAM with optimized
sequence times [65], maximum-echo sampling [48], dou-
ble-quantum filtering with selective J rewinding [66] and
ProFit of J-resolved spectra [62]. The selective homo-
nuclear Hartmann-Hahn transfer method, recently pro-
posed by Choi et al. [67], provides a spectral selectivity and
a sensitivity greater than those reported by previous
GABA-editing methods.
Diffusion tensor 1H-MRSI
In vivo diffusion spectroscopy can give insights into the
physico-chemical properties of the intracellular environ-
ment. One example is the hypothesis that the water
diffusion drop, associated with the development of ische-
mic cytotoxic edema, is caused not only by a water shift
from extra-cellular to intra-cellular space, but also by
reduced diffusion of intracellular water. This hypothesis
arises from diffusion spectroscopic studies, which have
demonstrated that purely intra-cellular metabolites, such as
NAA, also show a reduction of diffusion without any
compartmental shifts [68, 69]. Since diffusion for either
water or metabolites is anisotropic in white matter, it can be
characterized properly only by measuring the full diffusion
tensor. However, such a measure implies lengthy acquisi-
tion times, which can be reduced only by acquiring spectra
at a higher field. Recently, Ellegood et al. [70] measured
the diffusion tensor of NAA, Cho and Cr at 3 T in six
directions, in the brain of healthy volunteers, and demon-
strated that the principal diffusion direction for NAA is
consistent with the expected anatomic tract directions in the
white matter.
Fast 1H-MRSI
For the purpose of improving the temporal resolution of
metabolic brain mapping, different MR techniques, initially
developed for fast conventional MRI, have been applied to
multidimensional MRSI. Fast 1H-MRSI techniques im-
plemented at 3 T include echoplanar spectroscopic imaging
(EPSI) [71], parallel imaging with multicoil, multireceiver
arrangements [50] and spiral acquisitions [72]. Each
method comes with its own set of limitations and
advantages and is under development in order to insure
gainful application to the clinical routine. EPSI may be
useful for identifying mechanisms underlying the blood
oxygenation level dependence (BOLD) of the water signal
during brain activation studies, but mapping the signal
changes from brain metabolites is considerably more
challenging [71]. Parallel acquisition techniques require a
very demanding post-processing, and the resulting spectra
are prone to artifacts or quality losses [73, 74]. In effect,
although these techniques enable a significant reduction in
acquisition time, the resulting spectra suffer from reduced
SNR, and the need of multiple averaging to regain SNR
prevents its application to the clinical setting. Figure 4
illustrates the results of a new promising technique using a
prototype 3D PRESS sequence with an array spatial
sensitivity encoding technique (ASSET). Mayer et al. [72]
have recently presented a new promising method combin-
ing CT-PRESS with fast spiral MRSI. This method allows
the acquisition of multivoxel spectra with a nominal in-
plane resolution of 1.5×1.5 cm2 within 14 min, detecting
signals from NAA, Cr, Cho, Glu and myo-inositol with no
or only minor baseline distortions.
Conclusions
The advent of clinical scanners operating at 3 T is taking
structural and functional imaging to new levels and is
reinvigorating clinical brain spectroscopy. Many of the
challenges that initially limited the diffusion of 3-T MR
devices have been addressed by several strategies, the
awareness of which is important to improve the efficiency
of 3-T 1H-MRS and facilitate its application to the clinical
routine. In particular, the development of multichannel-
head coils that enables parallel imaging, the choice of
proper field-specific sequence parameters, the refinement
of correction algorithms and the application of special
spectral editing approaches have greatly improved and
added value to the diagnostic and research potentiality of
MRS. However, continued software and hardware devel-
opment and optimized sequence pulses are still needed to
reach the maximal efficiency of 3-T brain 1H-MRS.
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